BIO 2019 Notebook: Merck On Finding The Right Balance, Sandoz On The Next Wave Of Biosimilars, NORD On Patient Engagement

News and views from day three of the BIO International Convention: Merck’s Frazier champions both social justice and capitalism; Sandoz’s Pike thinks refinement of clinical data requirements will encourage biosimilar sponsors to target more moderate-selling biologics; National Organization for Rare Disorders’ Salstonstall sees impact from FDA reviewers talking to patients.

Along with enjoying Philadelphia's famous cheesesteaks (and beer), biotech execs address a wide range of topics, including social justice, capitalism, drug pricing, patient engagement, and biosimilar approval standards.